Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression
- 439 Downloads
Neuroplastic processes are thought to be involved in the pathophysiology of major depression. It has been reported that serum brain-derived neurotrophic factor (BDNF) is decreased in depressed patients.
Compare BDNF levels in depressed patients and healthy controls in platelet poor plasma and in washed platelets. Observe the effects of 8- and 24-week treatment with S-citalopram on these levels.
We assessed the levels of BDNF in platelet poor plasma and in washed platelets from 18 major depression patients, and compared them with 14 healthy controls. Blood samples were obtained from patients before and during treatment (8 and 24 weeks) with a selective serotonin reuptake inhibitor, S-citalopram.
A significant decrease in severity of depressive symptoms was observed from the first month of treatment with S-citalopram, and symptoms continued decreasing until the 6th month. Plasma BDNF levels in untreated patients appeared significantly increased (p < 0.01) but reached values similar to those of controls at the 24th week. In contrast, levels of platelet BDNF appeared significantly decreased (p < 0.05), but treatment also normalized levels so that values obtained were equivalent to those of controls.
Untreated depressed patients showed increased plasma BDNF levels and decreased platelet BDNF levels, as compared with control subjects, and tend to normalize during treatment with S-citalopram for 24 weeks, with BDNF reaching levels similar to those in healthy controls at the 24th week in both samples. We observed that improvement in depressive symptoms was accompanied by normalization of plasma and platelet BDNF levels.
KeywordsMajor depression Brain-derived neurotrophic factor (BDNF) Serum Plasma Platelets S-citalopram. Antidepressant
Brain-derived neurotrophic factor
Hamilton Depression Rating Scale
Enzyme-linked immunosorbent assays
BDNF in platelet poor plasma
BDNF in washed platelets
This work was partially supported by a grant from Hospital Clínic, Barcelona, by Ministerio de Ciencia e Innovación [SAF 2008-05674-C03-03 and Red HERACLES RD06/0009/1003], and by Ministerio de Sanidad [FIS CP04-00112, FIS PS09-0664] from the Spanish Government.
Registered in Current Controlled Trials as ISRCTN11216093—Changes in plasma and platelet Brain-Derived Neurotrophic Factor (BDNF) levels induced by S-citalopram in major depression
The authors report no biomedical financial interests or potential conflicts of interest.
- American Psychiatric Association (APA) (2003) DSM-IV-TR Manual Diagnóstico y Estadístico de los Trastornos Mentales. Masson, BarcelonaGoogle Scholar
- Diaz-Ricart M, Arderiu G, Estebanell E, Perez-Pujol S, Lozano M, White JG et al (2002) Inhibition of cytoskeletal assembly by cytochalasin B prevents signaling through tyrosine phosphosylation of Syk cortacin and focal adhesion kinase: studies under flow conditions. Am J Pathol 160:329–337PubMedCrossRefGoogle Scholar
- First MB, Spitzer RL, Gibbon M, Williams JBW (1999) Entrevista clínica estructurada para los Trastornos del Eje I del DSM-IV-SCID I. Masson, BarcelonaGoogle Scholar
- Stratz C, Trenk D, Bhatia HS, Valina C, Neumann FJ, Fiebich BL (2008) Identification of 5-HT3 receptors on human platelets: increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). Thromb Haemost 99(4):784–786PubMedGoogle Scholar